TXMD רווח למניה בשנים עשר החודשים האחרונים TherapeuticsMD Inc

The development of TherapeuticsMD, Inc. (TXMD) is based on the creation of prenatal drugs and the diversification of licenses. The 12-month EPS trend illustrates this dynamic, where the value of 0.01 reflects this status. However, success depends on insurance payouts and regulatory standards in reproductive medicine. The transition to a royalty model has reduced costs but created a dependency on partners' sales volumes.
TherapeuticsMD Corp (TXMD) - פילוחי מדדים ודוחות פיננסיים

Earnings per share (EPS TTM) represents the final annual financial result distributed across the total volume of shares outstanding. Growth in this metric confirms effective capital management and a real increase in shareholder value. By analyzing the EPS TTM dynamics of a company, an investor assesses the fundamental resilience of the business to market fluctuations. For TherapeuticsMD, Inc. (TXMD), this metric reflects the success of commercializing medical developments. Stable demand for innovation allows the company to mitigate the impact of macroeconomic cycles.